FAPI PET/CT在PCI术后冠心病中的应用:支架内再狭窄特征、MACE关联及降脂治疗短期调节有限
结果显示ACS患者FAPI摄取显著高于SCS,支架内再狭窄(ISR)斑块摄取显著高于非再狭窄(ISnR)斑块;探索性分析提示高摄取与MACE风险有升高趋势但生存差异不显著;短期降脂治疗未显著改变成纤维细胞活性。
要点
- ACS患者冠状动脉FAPI摄取显著高于SCS患者(SUVmax 4.06±1.81 vs 2.47±1.82,P<0.05)。
- ISR斑块FAPI摄取显著高于ISnR斑块(SUVmax 4.06±1.91 vs 1.69±0.72,P<0.0001)。
- 高FAPI摄取与MACE风险呈升高趋势,但生存差异未达显著。
核心结论
- FAPI PET/CT可无创评估成纤维细胞驱动的斑块活性,尤其在ISR中,并识别与MACE相关的高危冠状动脉斑块。
- 短期降脂治疗未显著改变成纤维细胞活性,需进一步研究其长期对斑块稳定性的影响。
研究设计与样本
- 患者行[¹⁸F]AlF-NOTA-FAPI-04 PET/CT,测量冠状动脉SUVmax和TBR,主要终点为MACE发生,次要终点为随访PET/CT中FAPI摄取变化。
- 同时评估降脂治疗对冠状动脉FAPI摄取的影响(FAPI-PLAQUE研究,NCT06280287)。
主要发现
- ACS患者FAPI摄取显著高于SCS患者:SUVmax 4.06±1.81 vs 2.47±1.82,TBR 4.51±2.20 vs 2.89±2.23,P<0.05。
- ISR斑块FAPI摄取显著高于ISnR斑块:SUVmax 4.06±1.91 vs 1.69±0.72,TBR 4.69±2.25 vs 1.88±0.91,P<0.0001。
- 探索性分析提示FAPI摄取升高与MACE风险有升高趋势,但生存差异不显著。
关键数值与推荐
- 冠状动脉FAPI摄取以SUVmax和TBR衡量,ACS组SUVmax 4.06±1.81、TBR 4.51±2.20。
- ISR斑块SUVmax 4.06±1.91、TBR 4.69±2.25;ISnR斑块SUVmax 1.69±0.72、TBR 1.88±0.91,组间P<0.0001。
- 短期降脂治疗未显著改变冠状动脉FAPI摄取。
临床怎么用
- 对PCI术后症状性患者,FAPI PET/CT可用于无创评估斑块成纤维细胞活性并辅助识别ISR。
- FAPI高摄取提示MACE风险升高趋势,可作为高危斑块评估的参考信息。
- 短期降脂治疗期间FAPI摄取可能无明显变化,不宜据此短期评估降脂疗效。
局限性
- MACE关联为探索性分析,生存差异未达统计学显著。
- 降脂治疗对FAPI摄取的评估限于短期随访,长期影响尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibroblast activation plays a key role in plaque instability and coronary artery disease (CAD) progression. In-stent restenosis (ISR) remains a major complication after percutaneous coronary intervention (PCI), increasing the risk of major adverse cardiovascular events (MACEs). This study primarily aimed to investigate whether coronary [¹⁸F]AlF-NOTA-FAPI-04 uptake is associated with major adverse cardiovascular events (MACEs) in symptomatic post-PCI patients, and secondarily to explore its ability to differentiate ISR from in-stent non-restenosis (ISnR) and to evaluate longitudinal changes under lipid-lowering therapy. METHODS: In this prospective single-centre observational cohort study, we enrolled symptomatic CAD patients with a history of PCI A total of 76 symptomatic CAD patients (30 with acute coronary syndrome [ACS] and 46 with stable coronary syndrome [SCS]) underwent FAPI PET/CT imaging. Twenty-two non-CVD individuals served as controls. Coronary SUVmax and TBR were measured. The primary endpoint was the occurrence of MACEs, while the secondary endpoint was changes in FAPI uptake on follow-up PET/CT. The effects of Lipid-lowering therapy(LLT) on coronary FAPI uptake were also evaluated. RESULTS: FAPI uptake was significantly higher in ACS (SUVmax: 4.06 ± 1.81, TBR: 4.51 ± 2.20) than in SCS (SUVmax: 2.47 ± 1.82, TBR: 2.89 ± 2.23, P < 0.05). ISR plaques exhibited markedly elevated FAPI uptake (SUVmax: 4.06 ± 1.91, TBR: 4.69 ± 2.25) compared to ISnR plaques (SUVmax: 1.69 ± 0.72, TBR: 1.88 ± 0.91, P < 0.0001). Exploratory analyses suggested a trend toward higher MACE risk with elevated uptake, but survival differences were not significant. CONCLUSION: FAPI PET/CT enables non-invasive assessment of fibroblast-driven plaque activity, particularly in ISR, and identifies high-risk coronary plaques linked to MACEs. While LLT did not significantly modify fibroblast activity in the short term, further studies are needed to explore its long-term effects on plaque stability. (FAPI-PLAQUE Study, NCT06280287).
引用
- Shi X, Wang L, Zhang H, et al. FAPI PET/CT in post-PCI coronary disease: in-stent restenosis characterization, MACE association, and limited short-term modulation by lipid-lowering therapy: FAPI athero trial. Eur J Nucl Med Mol Imaging. 2026. PMID: 42234008. doi:10.1007/s00259-026-07970-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。